Evaluating the Role of Amino Acid Infusions in Faster Recovery for Dengue Patients.

A Prospective, Randomized, Open-label trial to study the efficacy and safety of amino acids infusion as an add-on therapy in patients with dengue fever. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078475

Enrollment

Registered

2024-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B348- Other viral infections of unspecified site Health Condition 2: B348- Other viral infections of unspecified site

Interventions

Intervention1: IV Fuids with Astymin SN: Standard therapy with IV fluids along with Mix of AminoAcids Control Intervention1: Standard Care of therapy: IV Fluids with Symptomatic treatment

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients above 18 years of age diagnosed with dengue. 2) Adults confirmed dengue infection by positive NS1 antigen or IgM positive (ELISA Method). 3) All patients recommended for hospitalization and intravenous (IV) fluid therapy. 4) Diagnosed with Dengue fever without warning signs according to 2009 guidelines in In-Patient ward.

Exclusion criteria

Exclusion criteria: 1) Children below 18 years of age. 2) Adults and children with comorbid conditions associated with cardiovascular, kidney, liver, respiratory, tumour. 3) Critical dengue cases DHF with warning signs according to 2009 guidelines. 4) Pregnant women, Lactating women. 5) Patients with history of dengue vaccine in the recent past. 6) Hypersensitivity to previous amino acid infusion.

Design outcomes

Primary

Measure	Time frame
To study the efficacy of amino acids ampoules infusion when given along with standard therapy in patients with dengue fever in reducing the duration of fever and complications.Timepoint: Comparison of change in reduction in duration of fever compared to standard therapy	—

Secondary

Measure	Time frame
1. To evaluate the duration of hospital stay 2. Subjective self-assessment by the patient 3. Physician assessment of improvement 4. Safety assessment.Timepoint: ? Length of hospitalisation, ? Analgesic intake, and ? Other parameters like Rash, myalgia, arthralgia, headache, nausea, and conjunctivitis. Fevers, chills, and malaise amongst to be evaluated.	—

Countries

India

Contacts

Public ContactDeepan K

Sri Ramachandra Medical College and Research Institute

r.kavitha@sriramachandra.edu.in9444551410

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026